PT2315747T - Métodos e composições relacionados com oligossacarídeos sintéticos de beta-1,6 glucosaminas - Google Patents

Métodos e composições relacionados com oligossacarídeos sintéticos de beta-1,6 glucosaminas

Info

Publication number
PT2315747T
PT2315747T PT98006570T PT09800657T PT2315747T PT 2315747 T PT2315747 T PT 2315747T PT 98006570 T PT98006570 T PT 98006570T PT 09800657 T PT09800657 T PT 09800657T PT 2315747 T PT2315747 T PT 2315747T
Authority
PT
Portugal
Prior art keywords
methods
compositions relating
synthetic beta
glucosamine oligosaccharides
glucosamine
Prior art date
Application number
PT98006570T
Other languages
English (en)
Portuguese (pt)
Inventor
B Pier Gerald
Nifantiev Nikolay
Tsvetkov Yury
Gening Marina
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of PT2315747T publication Critical patent/PT2315747T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
PT98006570T 2008-07-21 2009-07-21 Métodos e composições relacionados com oligossacarídeos sintéticos de beta-1,6 glucosaminas PT2315747T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13549308P 2008-07-21 2008-07-21
US20815509P 2009-02-20 2009-02-20

Publications (1)

Publication Number Publication Date
PT2315747T true PT2315747T (pt) 2018-02-27

Family

ID=41570770

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98006570T PT2315747T (pt) 2008-07-21 2009-07-21 Métodos e composições relacionados com oligossacarídeos sintéticos de beta-1,6 glucosaminas

Country Status (19)

Country Link
US (5) US8492364B2 (https=)
EP (2) EP2315747B1 (https=)
JP (1) JP5555230B2 (https=)
KR (4) KR20110031393A (https=)
CN (2) CN102159540B (https=)
AU (1) AU2009274630B2 (https=)
BR (1) BRPI0916365A2 (https=)
CA (1) CA2731384C (https=)
CO (1) CO6341620A2 (https=)
DK (1) DK2315747T3 (https=)
ES (1) ES2660594T3 (https=)
HK (1) HK1254488A1 (https=)
IL (2) IL210789A (https=)
MX (2) MX2011000823A (https=)
NZ (1) NZ591103A (https=)
PT (1) PT2315747T (https=)
RU (1) RU2532911C2 (https=)
WO (1) WO2010011284A2 (https=)
ZA (1) ZA201101000B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
CA2797052A1 (en) 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
FR2967677B1 (fr) * 2010-11-18 2014-05-16 Centre Nat Rech Scient Derives de polysaccharides comprenant un motif alcene et reaction de couplage par chimie thio-clic
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
EP2854822B1 (en) 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
US9597433B2 (en) 2013-08-23 2017-03-21 University Of Houston System Non-pathogenic biofilms and uses thereof
KR102906912B1 (ko) 2016-09-02 2026-01-05 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
EP4061411A4 (en) * 2019-11-22 2023-11-29 Alopexx, Inc. METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG-CONTAINING MICROBES
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
CN112920237B (zh) * 2021-01-27 2022-06-14 山东大学 一种糖基受体、酶法合成寡糖链的快速分离的方法及应用
WO2022189361A1 (en) * 2021-03-08 2022-09-15 Universiteit Gent Conjugates including multiple saccharidic chains on a linear protein and uses in mammals feed
WO2025137258A1 (en) * 2023-12-21 2025-06-26 Board Of Trustees Of Michigan State University Development of pnag-based vaccines

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US2842049A (en) 1954-09-22 1958-07-08 Technicolor Corp Deacetylated chitin mordant
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4755381A (en) 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2039789A1 (en) 1990-04-27 1991-10-28 Samuel J. Danishefsky Calicheamicinone, derivatives and analogs thereof and methods of making the same
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5763191A (en) 1990-12-12 1998-06-09 Boehringer Mannheim Gmbh Universal binding film
DE4219159A1 (de) * 1992-06-11 1993-12-16 Boehringer Mannheim Gmbh Selbst assemblierende Monoschicht mit kurzkettigen Linkern
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
DK0594743T3 (da) 1991-07-12 1999-12-20 Pfizer Kontinuert cellelinje og vaccine mod aviær coccidia
DE69233012T2 (de) 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE156368T1 (de) 1991-12-06 1997-08-15 North Shore Univ Hospital Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DK0635132T4 (da) 1992-03-19 2008-08-25 Jackson H M Found Military Med Bredt reaktive opsoniske antistoffer, som reagerer med fælles stafylokok-antigener
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
CA2168509A1 (en) 1995-02-13 1996-08-14 Gregory C. Stalcup Orthopaedic milling guide with cutter lockout
AU7339996A (en) 1995-11-06 1997-05-29 Chugai Seiyaku Kabushiki Kaisha Sydnone imine derivatives
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US6677164B1 (en) * 1995-11-21 2004-01-13 Novartis Ag Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CA2284729A1 (en) * 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteins
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
JP2002511259A (ja) 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
AU4919699A (en) 1998-07-11 2000-02-01 Mhm Holdings Limited Vehicle seat, vehicle seat table and vehicle communication system
EP1096952B1 (en) 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CA2356849C (en) 1998-12-16 2008-06-03 Sca Hygiene Products Zeist B.V. Acidic superabsorbent polysaccharides
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2002094983A2 (en) 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US6962813B2 (en) 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CN1344722A (zh) 2001-10-19 2002-04-17 北京盈富安信科技有限公司 1→6连接的氨基葡聚寡糖和糖苷及其合成和应用
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
CA2530363C (en) 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
US9928522B2 (en) 2003-08-01 2018-03-27 Oath (Americas) Inc. Audience matching network with performance factoring and revenue allocation
JP2007501888A (ja) 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
CA2475736A1 (en) * 2004-07-23 2006-01-23 Cyrille Grandjean Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1863536A4 (en) 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
GB0505996D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
AU2007257436B2 (en) 2006-06-02 2013-05-02 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
CN100521341C (zh) 2006-08-30 2009-07-29 三洋电机株式会社 燃料电池及燃料电池用燃料供给装置
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US8454979B2 (en) 2009-02-20 2013-06-04 Meisho Co., Ltd. Immunopotentiating composition and process for producing same
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
EP2854822B1 (en) 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
US9759721B2 (en) 2013-01-22 2017-09-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
CN102159540B (zh) 2015-08-12
DK2315747T3 (en) 2018-02-26
US8492364B2 (en) 2013-07-23
US20190117754A1 (en) 2019-04-25
CN105085349A (zh) 2015-11-25
AU2009274630B2 (en) 2014-05-08
EP2315747A2 (en) 2011-05-04
CN105085349B (zh) 2018-02-09
MX2011000823A (es) 2011-04-11
IL210789A (en) 2015-11-30
KR20150003149A (ko) 2015-01-08
HK1254488A1 (en) 2019-07-19
ES2660594T3 (es) 2018-03-23
JP2011528710A (ja) 2011-11-24
US20160375117A1 (en) 2016-12-29
US9474806B2 (en) 2016-10-25
IL210789A0 (en) 2011-03-31
RU2011106332A (ru) 2012-08-27
WO2010011284A2 (en) 2010-01-28
CA2731384C (en) 2015-03-10
BRPI0916365A2 (pt) 2018-05-02
CO6341620A2 (es) 2011-11-21
JP5555230B2 (ja) 2014-07-23
US20110150880A1 (en) 2011-06-23
RU2532911C2 (ru) 2014-11-20
KR101573648B1 (ko) 2015-12-01
EP2315747B1 (en) 2017-12-06
MX351810B (es) 2017-10-27
WO2010011284A3 (en) 2010-04-22
CA2731384A1 (en) 2010-01-28
NZ591103A (en) 2013-02-22
KR20110031393A (ko) 2011-03-25
KR20160095192A (ko) 2016-08-10
IL242710B (en) 2019-07-31
US20220175904A1 (en) 2022-06-09
EP3312158A1 (en) 2018-04-25
AU2009274630A1 (en) 2010-01-28
CN102159540A (zh) 2011-08-17
US20140037633A1 (en) 2014-02-06
ZA201101000B (en) 2014-04-30
US11123416B2 (en) 2021-09-21
KR20150041178A (ko) 2015-04-15
US10034927B2 (en) 2018-07-31
EP2315747A4 (en) 2011-10-05
KR101785373B1 (ko) 2017-10-16

Similar Documents

Publication Publication Date Title
IL210789A0 (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
SI4269578T1 (sl) Sestava topne hialuronidaze
PL2440073T3 (pl) Synergistyczna mieszanina beta-galakto-oligosacharydów z wiązaniami beta-1,3 i beta-1,4/1,6
GB0712991D0 (en) Improvement in or relating to compositions
GB0712988D0 (en) Improvements in or relating to compositions
ZA201101958B (en) Modified lignin biopolymer useful in cleaning compositions
AP2011005777A0 (en) Methods and compositions related to thioesterase enzymes.
ZA201003041B (en) Chitosan composition
ZA201007022B (en) Carbohydrate gel
EP2471801A4 (en) GLYCOLIPIDES DERIVED FROM LIPOTHEICHOIC ACID AND COMPOSITIONS CONTAINING THESE GLYCOLIPIDS
ZA201100960B (en) Improvements in or relating to compositions
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
PL2429303T3 (pl) Kompozycje bogate w oligosacharydy arabinoksylanowe
GB0815180D0 (en) Improvements in or relating to insulation
GB0715605D0 (en) Improvements in or relating to compositions
SI2175888T1 (sl) Radiofarmacevtske spojine, obsegajoče polisaharide z dodanimi poliamini
GB0818002D0 (en) Improvements in or relating to ablutionary installations
IL208809A (en) Oligosaccharides containing disaccharide units and methods for preparing them
AP2744A (en) Phenanthrenone compounds, compositions and methods
GB2462719B (en) Improvements in or relating to analysing structural members
GB0724859D0 (en) Improvements in or relating to networks
GB0812466D0 (en) Improvements in and relating to coating compositions
GB0714811D0 (en) Improvements in or relating to compositions
GB0702532D0 (en) Improvements in or relating to rubber products
GB0603914D0 (en) Improvement in or relating to compositions